ClinicalTrials.gg
CompletedNCT05012670Updated Mar 15, 2024

Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

A Phase 1 interventional study of [14C]-Paxalisib Capsule in Healthy, sponsored by Kazia Therapeutics Limited. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Kazia Therapeutics Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2023, 3 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

Single-centre, open-label, non-randomised study to assess the mass balance recovery, PK, metabolite profile, and metabolite identification of a single oral dose of 14C labelled paxalisib ([14C] Paxalisib) in healthy male subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Kazia Therapeutics Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males.
  2. Aged 30 to 65 years inclusive at the time of signing .
  3. (BMI) of 18.0 to 35.0 kg/m2 as measured at screening.
  4. Must be willing and able to communicate and participate in the whole study.
  5. Must have regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools per day).
  6. Must provide written informed consent.
  7. Must agree to adhere to the requirements defined in study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1.
  2. Subjects who are, or are immediate family members of, a study site or sponsor employee.
  3. Evidence of current SARS-CoV-2 infection.
  4. History of any drug or alcohol abuse in the past 2 years.
  5. Regular alcohol consumption >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
  6. A confirmed positive alcohol breath test at screening or admission.
  7. Current smokers and those who have smoked within the last 12 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission.
  8. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months.
  9. Subjects with pregnant or lactating partners.
  10. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study.
  11. Subjects who have been administered IMP in an ADME study in the last 12 months.
  12. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening.
  13. abnormal clinical chemistry, haematology, or urinalysis as judged by the investigator (laboratory parameters are listed in study protocol).
  14. Confirmed positive drugs of abuse test result (drugs of abuse tests are listed in study protocol)
  15. Positive surface antigen (HBsAg), virus antibody (HCV Ab), or (HIV) antibody results
  16. Evidence of renal impairment at screening, as indicated by an estimated (CLcr) of \<80 mL/min using the Cockcroft-Gault equation.
  17. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory disease, neurological, or psychiatric disorder, as judged by the investigator.
  18. History of clinically significant GI disease, especially peptic ulceration, GI bleeding, ulcerative colitis, Crohn's Disease, or Irritable Bowel Syndrome.
  19. Any history of pre-diabetes, diabetes mellitus (any type), or hyperglycaemia. At screening, fasting blood glucose and must be within the normal range.
  20. History or presence of significant dermatological disorders or skin rashes, as judged by the investigator.
  21. Subject had a of >450 msec based on at screening or at pre dose, or a history of additional risk factors for Torsades de Pointe (e.g., hypokalaemia, hypomagnesia, a family history of long QT syndrome).
  22. Serious adverse reaction or serious to any drug or the formulation .
  23. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active.
  24. Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood.
  25. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day) within 14 days before IMP administration (see Section 11.4). COVID-19 vaccines are accepted concomitant medications, except for within 72 h of dosing. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the investigator.
  26. Subjects who have had a COVID-19 vaccine within 72 h (3 days) before IMP administration.
  27. History of GI surgery (with the exception of appendectomy unless it was performed within the previous 12 months).
  28. Acute diarrhoea or constipation in the 7 days before the predicted Day 1. If screening occurs >7 days before the Day 1, this criterion will be determined on Day 1. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than 3 times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day.
  29. Failure to satisfy the investigator of fitness to participate for any other reason.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]-Paxalisib Capsule

    Subjects will be dosed on the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects will remain resident in the clinical unit until 168 h post dose (Day 8) and this may be extended up to a maximum of 48 h (i.e., up to Day 10).

    Drug: [14C]-Paxalisib Capsule

Interventions

  • Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.

    Also known as: Phosphoinositide 3-kinase (PI3K) Inhibitor

06

What researchers measure

Primary outcomes

  1. To determine the mass balance recovery after a single oral dose of carbon-14 ([14C])-Paxalisib

    Mass balance recovery of total radioactivity (TR) in all excreta (urine and faeces): CumAe (amount excreted) and Cum%Ae

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  2. To provide plasma samples for metabolite profiling and structural identification

    Collection of plasma samples for metabolite profiling, structural identification, and quantification analysis of paxalisib metabolites

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  3. To provide urine samples for metabolite profiling and structural identification

    Collection of urine samples for metabolite profiling, structural identification, and quantification analysis of paxalisib metabolites

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  4. To provide faecal samples for metabolite profiling and structural identification

    Collection of faecal samples for metabolite profiling, structural identification, and quantification analysis of paxalisib metabolites

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

Secondary outcomes

  1. To determine the routes and rates of elimination of [14C]-Paxalisib

    Calculation of Ae, %Ae, CumAe, and Cum%Ae for TR by interval in urine and faeces

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  2. To identify the chemical structure of each metabolite accounting for more than 10% (in plasma) of circulating TR or metabolites in excreta (urine and faeces) that account for more than 10% of the administered radioactive dose

    Identification of the chemical structure of each paxalisib metabolite accounting for more than 10% by area under the curve (AUC) of circulating TR in plasma to identify major metabolites, and identification of each metabolite in excreta (urine and faeces) that accounts for more than 10% of the administered radioactive dose

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  3. To explore the Cmax pharmacokinetic (PK) parameter of paxalisib following administration of [14C] Paxalisib

    Assessment of the PK of an oral \[14C\]-Paxalisib formulation by measurement of paxalisib in plasma including but not limited to Cmax parameter

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  4. To explore the Tmax pharmacokinetic (PK) parameter of paxalisib following administration of [14C] Paxalisib

    Assessment of the PK of an oral \[14C\]-Paxalisib formulation by measurement of paxalisib in plasma including but not limited to Tmax parameter

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  5. To explore the AUC(0-last) and AUC(0-inf) pharmacokinetic (PK) parameter of paxalisib following administration of [14C] Paxalisib

    Assessment of the PK of an oral \[14C\]-Paxalisib formulation by measurement of paxalisib in plasma including but not limited to AUC(0-last) and AUC(0-inf) parameter

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  6. To explore the Cmax pharmacokinetic (PK) of TR following administration of [14C] Paxalisib

    Assessment of the PK of an oral \[14C\]-Paxalisib formulation by measurement of TR in plasma including but not limited to Cmax parameter

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  7. To explore the Tmax pharmacokinetic (PK) of TR following administration of [14C] Paxalisib

    Assessment of the PK of an oral \[14C\]-Paxalisib formulation by measurement of TR in plasma including but not limited to Tmax parameter

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  8. To explore the AUC(0-last) and AUC(0-inf) pharmacokinetic (PK) of TR following administration of [14C] Paxalisib

    Assessment of the PK of an oral \[14C\]-Paxalisib formulation by measurement of TR in plasma including but not limited to AUC(0-last) and AUC(0-inf) parameter

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  9. To evaluate the extent of distribution of TR into blood cells

    Evaluation of whole blood:plasma concentration ratios for TR

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  10. To provide adverse event (AE) safety information for paxalisib

    To provide safety information for paxalisib by assessing adverse events.

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  11. To provide blood pressure vital sign safety information for paxalisib

    Measuring and assessing blood pressure in standard clinical units and against reference range.

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  12. To provide heart rate vital sign safety information for paxalisib

    Measuring and assessing heart rate in standard clinical units against reference range.

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  13. To provide oral temperature vital sign safety information for paxalisib

    Measuring and assessing oral temperature in standard clinical units against reference range.

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  14. To provide respiratory rate vital sign safety information for paxalisib

    Measuring and assessing respiratory rate in standard clinical units against reference range .

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  15. To provide electrocardiogram (ECG) safety information for paxalisib

    Determination of standard ECG parameters including but not limited to PR interval, QRS duration, in standard clinical units against reference range

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  16. To provide physical examination safety information for paxalisib

    Assessment of standard clinical whole-body targeted (symptom-driven) physical examination including but not limited to e.g. general appearance, dermatological

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  17. To provide hematology laboratory safety testing information for paxalisib

    Measuring and assessing standard array of hematology parameters (e.g. white blood cell count) in standard clinical unit against reference range.

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

  18. To provide clinical chemistry laboratory safety testing information for paxalisib

    Measuring and assessing standard array of clinical chemistry parameters (e.g. cholesterol) in standard clinical unit against reference range

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

Other outcomes

  1. To assess the urine PK of paxalisib following administration of [14C] Paxalisib

    Determination of \[14C\] Paxalisib and calculation of Ae (amount excreted), CumAe (cummulative amount excreted), %Ae (fraction of dose excreted) and Cum%Ae (cummulative fraction of dose excreted) as appropriate for paxalisib in urine

    Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)

07

Study locations

1 site
  • Quotient Sciences
    Nottingham, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Mar 2023, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Aug 19, 2021
StartActual
Aug 18, 2021
Primary completionActual
Mar 30, 2023
CompletionActual
Jan 30, 2024
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05012670
Lead sponsor
Kazia Therapeutics Limited
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Aug 19, 2021
Start date
Aug 18, 2021
Primary completion
Mar 30, 2023
Completion
Jan 30, 2024
Last update
Mar 15, 2024

Study contacts

Philip Evans, MBChB, MRCS
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GDC-0084

Start the discussion